Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

NSAID

Therapeutic area intelligence for NSAID with 9 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
9
Catalysts
0
Companies
7

Companies

Aspar Pharmaceuticals Ltd →
Aurobindo Pharma →
Hetero Labs →
Micro Labs →
Novitium Pharma →
Sciegen Pharmaceuticals →
Strides Pharma →

Assets

Almus →
Aurobindo →
Etodolac →
FDA →
Naproxen →
Piroxicam →

Recent signals

(9)
RegulatoryAugust 6, 2026

FDA Grants AP Status for Piroxicam ANDA206152 by Micro Labs

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status of 'AP' for Piroxicam submitted by Micro Labs.

RegulatoryJuly 24, 2026

Aurobindo Pharma's Diclofenac Sodium ANDA076152 Receives AP Status

Aurobindo Pharma USA has received an Abbreviated New Drug Application (ANDA) approval status for Diclofenac Sodium.

RegulatoryJuly 23, 2026

FDA Grants Approval for Aurobindo's Etodolac ANDA214872

The FDA has granted approval for Aurobindo Pharma's ANDA214872 for Etodolac.

RegulatoryJuly 9, 2026

FDA Grants AP Status for Hetero Labs' Naproxen ANDA215776

The FDA has granted abbreviated approval (AP) status for Hetero Labs' ANDA for Naproxen.

RegulatoryJuly 8, 2026

FDA Accepts Supplement for Naproxen by Novitium Pharma

The FDA has accepted a supplemental application for Naproxen from Novitium Pharma.

RegulatoryJuly 8, 2026

FDA Grants Approval for Naproxen Sodium ANDA212199 by Sciegen Pharmaceuticals

The FDA has granted approval for ANDA212199, a supplemental application for Naproxen Sodium submitted by Sciegen Pharmaceuticals.

RegulatoryJuly 1, 2026

Strides Pharma's Piroxicam ANDA206136 Receives AP Status from FDA

Strides Pharma's ANDA for Piroxicam has received an Abbreviated Approval (AP) status from the FDA.

StrategyJuly 1, 2026

FDA Grants AP Status for Piroxicam ANDA210347 by Strides Pharma

Strides Pharma has received an Abbreviated New Drug Application (ANDA) approval for Piroxicam.

RegulatoryJune 24, 2026

Aspar Pharmaceuticals recalls Ibuprofen 200mg Tablets due to foil perforations

Aspar Pharmaceuticals Ltd is recalling specific batches of Ibuprofen 200mg Tablets due to foil perforations in some blisters.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.